Skip to main content

Table 6 Correlations of clinical features with systemic sclerosis-associated autoantibodies

From: Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features

Quantitative traits Clinical data
Age at disease onset n Mean ± SD (years) P*
   Total 781 47.7 (14.2)  
   Anti-centromere 273 51.3 (12.5) < 0.0001
   Anti-topoisomerase I 238 46.0 (14.0) 0.0076
   Anti-fibrillarin 12 38.8 (16.0) 0.0404
   Anti-U1-RNP 39 38.2 (15.0) < 0.0001
   Anti-La 15 37.9 (18.1) 0.0431
   Autoantibody-negative 36 52.9 (14.7) 0.0205
Rodnan skin score n Mean score ± SD P
   Total 750 10.2 (9.4)  
   Anti-centromere 275 6.4 (6.0) < 0.0001
   Anti-topoisomerase I 227 14.1 (9.7) < 0.0001
   Anti-RNA polymerase 27 15.7 (11.7) 0.0091
   Anti-fibrillarin 10 21.2 (15.0) 0.0108
   Anti-U1-RNP 35 6.9 (9.2) 0.0053
Erythrocyte sedimentation rate n Mean ± SD (mm/hour) P
   Total 741 19.46 (16.7)  
   Anti-topoisomerase I 227 22.95 (19.1) 0.0002
   Anti-PM-Scl 36 12.19 (9.4) 0.0014
   Anti-Ro52 167 22.05 (18.8) 0.0374
   Anti-Ro60 53 28.47 (19.6) < 0.0001
   Anti-La 16 28.56 (20.1) 0.0447
  1. PM-Scl = polymyositis and scleroderma; RNP = ribonucleoprotein; SSc, systemic sclerosis. *P-value calculated by Mann-Whitney rank-sum test for comparison of antibody-positive vs antibody-negative patients.